Mankind unit acquires full control of Upakarma Ayurveda for ₹75 Lakhs
Mankind Lifesciences Private Limited, a wholly owned subsidiary of Mankind Pharma, has acquired the remaining 10% stake in Upakarma Ayurveda Private Limited for ₹75 Lakhs. The transaction, completed on June 2, 2026, via a Share Purchase Agreement, makes Upakarma a wholly owned subsidiary of Mankind Lifesciences. The acquisition, classified as a Related Party Transaction at arm’s length, was disclosed under Regulation 30 of the SEBI Listing Regulations. Upakarma Ayurveda, incorporated in 2017, operates in the ayurvedic and nutraceutical sector and reported a turnover of ₹18.02 Crores for FY26.
*this image is generated using AI for illustrative purposes only.
Mankind Lifesciences Private Limited, a wholly owned subsidiary of mankind pharma , has acquired the remaining 10% stake in Upakarma Ayurveda Private Limited for ₹75 Lakhs. The transaction was completed on June 2, 2026, through a Share Purchase Agreement with Kaushcorp Media LLP, thereby making Upakarma a wholly owned subsidiary of Mankind Lifesciences and a step-down subsidiary of Mankind Pharma. The acquisition is classified as a Related Party Transaction conducted at arm’s length, with no interest held by the promoters or promoter group of Mankind Pharma in the deal.
Transaction Details
The cash consideration of ₹75 Lakhs for the 10% stake is payable in two tranches as per the Share Purchase Agreement. Following this acquisition, Mankind Lifesciences holds 100% of the shareholding in Upakarma Ayurveda. The acquisition was disclosed to the exchanges under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Target Entity Profile
Upakarma Ayurveda Private Limited, incorporated on November 28, 2017, operates in the ayurvedic, herbal, and nutraceutical products sector. The entity became a step-down subsidiary of Mankind Pharma on November 9, 2022. The company has a presence in India and reported a turnover of ₹18.02 Crores for the financial year 2025-26.
Financial Performance of Upakarma Ayurveda
The target entity has demonstrated varying revenue trends over the past three years. The turnover figures for the last three financial years are detailed below:
| Financial Year | Turnover (₹ in Crores) |
|---|---|
| 2025-26 | 18.02 |
| 2024-25 | 13.06 |
| 2023-24 | 23.04 |
Upakarma Ayurveda has an authorized share capital of ₹2.00 Crores and a paid-up share capital of ₹1.80 Crores. The acquisition is expected to enable Mankind Pharma to achieve better operational efficiencies through streamlined processes within the subsidiary.
Historical Stock Returns for Mankind Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.70% | -2.78% | +4.73% | +6.68% | +0.03% | +65.44% |
How does Mankind Pharma plan to stabilize and reverse the revenue volatility observed in Upakarma Ayurveda over the past three years?
What specific operational efficiencies and cost synergies does Mankind expect to unlock by bringing Upakarma under full ownership?
Will this acquisition lead to increased capital allocation towards the digital marketing and distribution of Upakarma's nutraceutical products?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
